3 mg semaglutide: the strength that belongs to a different medicine

You've seen a 3 mg semaglutide tablet advertised and wondered if it's for you

It's an easy mistake. Semaglutide is the active ingredient in several medicines, and search results don't always separate them cleanly. When people first hear that Wegovy tablets have arrived in the UK (the MHRA approved them on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management) they often search for the doses they've read about in passing. The 3 mg figure surfaces because it exists: it's the starting strength of Rybelsus, the semaglutide tablet Novo Nordisk launched for people managing type 2 diabetes.

Rybelsus and Wegovy tablets are not the same product. They share a molecule, but they're formulated differently, dosed differently, and licensed for different conditions. Rybelsus comes in 3 mg, 7 mg and 14 mg tablets. Wegovy tablets come in 1.5 mg, 4 mg, 9 mg and 25 mg. These two dose ladders do not overlap. If a seller is offering you a 3 mg tablet as a weight-loss treatment, that is not Wegovy, and the MHRA has not licensed Rybelsus for weight management. Understanding how the Wegovy dose schedule is structured is a useful starting point if you want to see how the licensed weight-loss version actually works.

The MHRA's guidance is clear: semaglutide medicines for weight management and for diabetes are distinct authorisations. A prescriber working within UK licensing cannot prescribe Rybelsus off-label for weight loss in the same way Wegovy is prescribed.

What the licensed Wegovy tablet dose schedule actually looks like

The Wegovy weight-loss tablet schedule starts at 1.5 mg once daily. Patients spend at least a month at each level before moving up, a pacing that's designed to let the body adjust, reducing the likelihood of nausea and other gastrointestinal effects that are common at the start of treatment. After 1.5 mg comes 4 mg, then 9 mg, then the 25 mg maintenance dose. That's the full ladder, and there is no 3 mg rung on it.

One practical difference people notice immediately: the tablets need no refrigeration. They're taken first thing in the morning on an empty stomach, swallowed whole with a small amount of plain water, and you wait at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines. That's quite different from the injectable Wegovy pen, which stays in the fridge. For people who travel frequently or simply prefer not to handle injections, the tablet option removes a real logistical friction point. If you'd like to compare the two forms side by side, the Wegovy overview page covers both.

Trial data for the oral tablet (the OASIS 4 phase-3 trial, 64 weeks, reported by Novo Nordisk alongside the UK approval) showed an average weight loss of around 13.6% among participants, rising to roughly 17% among those who remained fully adherent throughout. That last figure is worth reading carefully: it applies to full adherence, not to the average participant. The NHS has not yet appraised the oral tablet through NICE, so it is currently available through private prescription only. Wegovy tablets are a prescription-only medicine; a clinician assesses whether they are appropriate for you before anything is dispensed.

Why the 3 mg / 7 mg / 14 mg tablet strengths matter in a safety context

This isn't just a labelling technicality. If someone sources what they believe to be a semaglutide weight-loss tablet and receives Rybelsus at 3 mg, the licensed indication, the dose titration, the target maintenance dose and the monitoring expectations are all different. Taking a diabetes medicine without the right clinical oversight is a genuine risk, not because the molecule is dangerous in itself, but because the prescribing context around it (blood glucose monitoring, interactions with other diabetes treatments, dose progression) is built around a different patient population and a different therapeutic goal.

The MHRA has warned publicly about weight-loss medicines sold through unverified online routes, and that problem extends beyond injectable pens. Any seller offering semaglutide tablets for weight loss without a prescription is operating outside UK law. You can check whether a pharmacy is legitimately registered using the GPhC pharmacy register, it takes thirty seconds and it tells you immediately whether the site you're looking at is operating legally.

If you have type 2 diabetes and a prescriber has suggested Rybelsus, that's a separate conversation to have with your GP or diabetes team, and our semaglutide 1 mg page may also be a helpful reference if you're trying to understand how injectable dose strengths compare to the tablet options you've seen discussed. This page is for people looking for a weight-loss medicine; the weight-loss treatments overview covers what's licensed, what the evidence shows, and how to access treatment safely.

What to do if Wegovy tablets look right for you

The licensed eligibility for Wegovy tablets is adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't determine suitability, a prescriber looks at the whole picture, including other medicines you take and your medical history.

A question our prescribers hear fairly regularly is whether patients who are already on the 2.4 mg weekly injectable can switch straight to the tablet. The answer is yes, subject to clinical assessment: those established on the injection dose may move directly to the 25 mg maintenance tablet rather than restarting the full escalation. If you want to understand exactly how doses progress across the full range before that conversation, the 5mg semaglutide dosing chart gives a clear visual reference for where each strength sits in the overall schedule. That's a conversation to have during a consultation, not a decision to make unilaterally.

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not a decision tree. If you order before noon on a weekday and are approved as clinically suitable, treatment is dispatched the same day via DPD, arriving the next working day in plain packaging. The full cost covers consultation, prescription, treatment and delivery together, with no subscription and no auto-renewals. You can see how the semaglutide dosing process works in more detail, or take a look at what accessing Wegovy through a regulated UK pharmacy involves before you decide. When you're ready, starting a free consultation takes a few minutes and puts your answers in front of a prescriber the same day.